Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)

You'll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prevention in patients with CV risks.

Most data suggest that CGRP antagonists have minimal CV impact. But it's mostly short-term and in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with Aimovig (erenumab)...prompting labeling updates.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote